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ABSTRACT 
Purpose. An enhanced use of glycolysis and production of carbonic and lactic acids, actively 
contribute to the extracellular acidosis, promoting tumor development, progression and 
invasiveness. pH (Low) Insertion Peptides (pHLIP
®
 peptides) pertain to the class of pH-sensitive 
agents able of sensing pH at the cellular surface and delivery of imaging and/or therapeutic 
agents to the cancer cells in tumors.  
Procedures. We investigated targeting of highly metastatic 4T1 mammary carcinoma and 
biodistribution of different pHLIP
®
 variants conjugated with various fluorescent dyes. To reveal 
similarities and differences between investigated constructs and to identify the best pHLIP
®
 
peptide based constructs for clinical applications we employed a statistical hierarchical clustering 
and multivariate linear regression analyses. 
Results. The highest tumor targeting with low accumulation in liver, kidney and muscle was 
observed for Alexa546-Var3, which also targets 500 m sized metastatic lesions in lungs. 
Conclusions. Fluorescent pHLIP
®
 peptides could be used for diagnostic and treatment (surgical 
resection) of primary tumors and submillimeter metastatic lesions. 
 
KEYWORDS: Imaging, tumor acidity, fluorescent-guided surgery, targeting of submillimeter 
metastatic lesions 
 
  
INTRODUCTION 
A common specific feature of tumor microenvironment is a hypoxia and an extracellular acidosis 
[1]. The acidification of extracellular space leads to reverse of a pH transmembrane gradient in 
cancer cells [2-3]. Previous research showed that the acidic extracellular pH, promotes invasion 
and metastasis of cancer cells [4-5]. The highly proliferative cancer cells (metabolically active 
cells) are the most acidic. Thus, targeting of tumor acidity might be developed as an important 
predictive clinical marker of tumor aggressiveness and invasiveness. However, a sharp proton 
concentration gradient exists near the surface of cancer cells. Thus, the best approach will be to 
access acidity in close proximity to cancer cells in tumors.  
 
We have introduced family of pH Low Insertion Peptides (pHLIP
®
 peptides), which represents a 
unique class of water-soluble membrane polypeptides capable to undergo a pH-dependent 
membrane-associated folding [6-7]. pHLIP
®
 peptides possess dual delivery capabilities, making 
use of the energy of folding to translocate polar cargo molecules across phospholipid bilayer of 
membrane and/or tether molecules to the cell surface [8]. Also, the process of peptide folding 
within a membrane ensures a high cooperativity of the transition, which cannot be achieved by 
simple diffusion [9-11]. Since pHLIP
®
 peptides are in equilibrium between membrane-bound 
and non-bound configurations at normal pH they are capable of sensing pH at the cell surface. 
As soon as pH drops (even on a half of pH unit), the Asp and Glu residues are protonated 
enhancing affinity of peptides to membrane, which triggers folding in membrane and release of 
energy.  Depending on pHLIP
®
 sequence protonatable residues could be differently located on 
membrane surface, which directly affects the rate of the protonation events at various pHs, and 
thus pK of peptides insertion into the membrane. We have introduced family of pHLIP
®
 peptides 
with pK of insertion varying from 4.5 to 6.5 and confirmed that tumor targeting is indeed pH-
dependent [9]. Three pHLIP
®
 variants, WT, Var3 and Va7 were selected as lead candidates for 
pH-specific delivery of imaging and therapeutic agents to tumors of different origins. We 
showed previously targeting of tumors by fluorescently-labeled WT-, Var3- and Var7 pHLIP
®
 
peptides as well by the pHLIP-Fluorescence Insertion REporter (pHLIP
®
-FIRE) [9, 12-14]. One 
of the very attractive potential clinical applications of fluorescent pHLIP
®
 peptides might be a 
fluorescence-guided surgical resection of tumors. The proliferative cancer cells will light up 
most of all targeted by the fluorescent pHLIP
®
 agents. However, in addition to the peptide 
sequence variation, fluorescent dyes (which are usually about one third of pHLIP
®
 peptides 
mass) can affect and alter tumor targeting and biodistribution of pHLIP
®
 compounds. In the 
present study, we compared targeting of mammary tumors and biodistribution of different 
pHLIP
®
 variants conjugated with eight fluorescent dyes with the main purpose to identify the 
best pHLIP
® 
constructs for various clinical uses. Also, we demonstrated staining of sub-
millimeter metastatic lesions in lungs by Alexa546-Var3.  
 
MATERIALS AND METHODS 
Conjugation of pHLIP® peptides with fluorescent dyes 
pHLIP® variants were prepared by solid-phase peptide synthesis using Fmoc (9-
fluorenylmethyloxycarbonyl) chemistry and purified by reverse phase chromatography by CS 
Bio. pHLIP® variants were conjugated with Alexa546-, Alexa647-, Alexa750-, Cy5.5-, DyL680-, 
DyL680-4xPEG-maleimide (Life Technologies) and IR680-, IR800-maleimide (LiCor 
Biosciences) in DMF (dimethylformamide) at a ratio of 1:1 and incubated at room temperature 
for about 8 hours and then at 4ºC until the conjugation was completed. The reaction progress and 
purity was monitored by reverse phase HPLC to ensure absence of free dyes in the final solution. 
The products were lyophilized and characterized by SELDI-TOF mass spectrometry. The 
concentration of constructs was determined by absorbance using the following molar extinction 
coefficients: 556=104,000 M
−1
·cm
−1
 (for Alexa546-pHLIPs), 650=239,000 M
−1
·cm
−1
 (for 
Alexa647-pHLIPs), 753=290,000 M
−1
·cm
−1
 (for Alexa750-pHLIPs), 673=209,000 M
−1
·cm
−1
 (for 
Cy5.5-pHLIPs), 672=165,000 M
−1
·cm
−1
 (for IR680-pHLIPs), 778=300,000 M
−1
·cm
−1
 (for 
IR800-pHLIPs), 684=140,000 M
−1
·cm
−1
 (for Dy680-pHLIPs) and 684=180,000 M
−1
·cm
−1
 (for 
DyP680-pHLIPs).  
 
Absorbance and fluorescence measurements  
Absorbance and fluorescence measurements were carried out on a Genesys 10S UV-Vis 
(Thermo Scientific) spectrophotometer and a SpectraMax M2 (Molecular Devices) 
spectrofluorometer, respectively. The excitation wavelengths were the following for different 
constructs: 550 nm for Alexa546-pHLIPs; 650 nm for Alexa647-pHLIPs, 673 nm for Cy5.5-
pHLIPs; 680 nm for IR680-pHLIPs, Dy680-pHLIPs and DyP680-pHLIPs; 750 nm for 
Alexa750-pHLIPs and 780 nm for IR800-pHLIPs.   
 
Cell lines  
The 4T1 and 4T1-GFP mouse mammary tumor cell lines were obtained from the American Type 
Culture Collection and cultured in RPMI medium supplemented with 10% fetal bovine serum, 10 
μg/mL of ciprofloxacin in a humidified atmosphere of 5% CO2 and 95% air at 37°C.  
 
 
Tumor mouse models 
Mammary tumors were established by subcutaneous injection of 4T1 cells (8x10
5
 cells/0.1 
ml/flank) in the right flank of adult female BALB/c mice (about 20 g weight) obtained from 
Harlan Laboratories. For the metastatic tumor model, 10
6
 4T1-GFP cells/50 l were injected 
subcutaneously in the mammary fat pad. After approximately 3 weeks, the primary tumor 
metastasized in the lungs. All animal studies were conducted according to the animal protocol 
AN04-12-011 approved by the Institutional Animal Care and Use Committee at the University of 
Rhode Island, in compliance with the principles and procedures outlined by NIH for the Care and 
Use of Animals.  
 
Fluorescent imaging of organs and tissue 
When tumors reached approximately 5-6 mm in diameter tail vein injections of 100 L of 40 M 
of fluorescent pHLIP
®
 peptides were performed. Animals were euthanized at 2, 4, 24 and 48 
hours post-injection, and necropsy was performed immediately after euthanization. Tumors and 
major organs of BALB/c mice were collected for imaging on a FX Kodak in-vivo image station. 
Fluorescence intensity was obtained via analysis of images by using Kodak software. The 
contrast index (CI) was calculated according to the equation:  
𝐶𝐼 =
𝐹𝑡𝑢𝑚𝑜𝑟 − 𝐹𝑏𝑎𝑐𝑘𝑔
𝐹𝑚𝑢𝑠𝑐𝑙𝑒 − 𝐹𝑏𝑎𝑐𝑘𝑔
 
where Ftumor , Fmuscle and Fbackg are the mean fluorescence intensities of tumor, muscle and 
background signal of the same organ from untreated mice, respectively. Fluorescent images of 
metastatic lesions in lungs were acquired at 4 and 10x magnification using an Olympus IX71 
inverted fluorescence microscope. 
 
Multivariate Statistical Analysis 
Statistical agglomerative hierarchical clustering algorithm was applied to the database of 24 
objects comprising from 3 different pHLIP
®
 variants (WT, Var3, and Var7) conjugated with 8 
fluorescent dyes, namely Alexa546 (Al546), Alexa647 (Al647), Alexa750 (Al750), Cy5.5 (Cy5), 
IR680 (IR680), IR800 (IR800), DyL680 (Dy680) and DyL680-4xPEG (DyP680), measured at 
time points of 2 and 4 hours.  The normalized fluorescent parameters measured in tumor (NFT – 
normalized fluorescence in tumor), muscle (NFM – normalized fluorescence in muscle), kidney 
(NFK – normalized fluorescence in kidney), and liver (NFL – normalized fluorescence in liver) 
and averaged over a number of mice tested per experiment were used in analysis.  The Euclidean 
metric was employed to compute distances and Ward’s minimum within-cluster variance 
criterion was applied as an amalgamation (linkage) rule. The results are presented in a form of 
hierarchical tree, or dendrogram, with height scaled to percentage for convenience of 
interpretation. The calculations were performed using the hclust function in R. 
 
Multivariate linear regression analysis was applied on a combined (not averaged) response of 
four fluorescent variables represented by NFT, NFM, NFL and NFK, and three categorical 
predictors represented by Time (2, 4 and 24 hours), Dye (8 various fluorescent dyes), and 
pHLIP
®
 variants (Var3, Var7, and WT).  The maximum-likelihood method was used to estimate 
a matrix of regression coefficients, which in the multivariate linear model is equivalent to 
equation-by-equation least squares estimation for the individual responses. Commonly employed 
multivariate analysis of variance (MANOVA) procedures such as Pillai-Bartlett Trace, 
Hotelling-Lawley Trace, and Wilks’s Lambda [15] were used to take into account correlation in 
four fluorescent variables and to check overall statistical significance of three categorical 
predictors. The calculations were performed using the lm and manova functions in R. 
 
RESULTS 
The focus of our work was targeting of mammary tumors by three pHLIP
®
 variants recently 
selected for pre-clinical development [7, 9, 13]: 
WT:   ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT    
Var3: ACDDQNPWRAYLDLLFPTDTLLLDLLW    
Var7: ACEEQNPWARYLEWLFPTETLLLEL 
Each peptide had a single Cys residue at the N-terminus for conjugation with fluorescent dyes. 
We used fluorophores emitting at visible and near-infrared wavelengths: Alexa546, Alexa647, 
Alexa750, Cy5.5, Dy680, DyP680, IR680, IR800 (see Table 1). The molecular weights and 
HPLC retention times, reflecting the hydrophobicity of the investigated fluorescent constructs, 
are also given in Table 1. The absorption and emission spectra of fluorescent constructs are 
shown in Supplementary Figure S1. The fluorescence was measured in absence and presence of 
POPC liposomes to mimic behavior of the fluorescent constructs in membrane-unbound and 
membrane-bound forms. . 
 
With the selected fluorescent dye, Alexa750, we also investigated performance of the following 
pHLIP® sequences, where the N-terminal end of the peptides contains six negatively-charged 
Asp residues for the enhancement of constructs solubility: 
Var3M: ACDDDDDDPWQAYLDLLFPTDTLLLDLLW  
Var7M: ACDDDDDDPWQAYLDLFPTDTLALDLW   
In addition, we studied biodistribution of the constructs, where Alexa546 and Cy5.5 fluorescent 
dyes were attached to the single Cys residue at the membrane-inserting C-terminus of the Var3 
pHLIP® peptide: 
Var3-C: ADDQNPWRAYLDLLFPTDTLLLDLLCW 
 
To test tumor targeting  by fluorescent pHLIP® peptides we selected the highly tumorigenic and 
invasive 4T1 mammary carcinoma model, which mimics stage IV of human breast cancer [16-
18], and  is known to be acidic [19] and targeted very well by pHLIP® peptides [14].  This 
transplantable cancer cell line can spontaneously metastasize from the primary tumor in the 
mammary gland to multiple distant sites [20-21]. Fluorescent pHLIP® peptides were 
administrated intravenously and at different time points ranging from 2 to 48 hours, animals 
were euthanized, tumor, kidney, liver and muscle were collected and imaged immediately. The 
representative fluorescent images of tissue and organs obtained at 4 hours after the constructs 
administration are shown on Figure 1. Very good tumor targeting was observed by all 
fluorescent pHLIP
®
 peptides .The fluorescent images obtained at different time points were used 
to calculate changes of the mean surface fluorescence intensity in tissue and organs (Figure 2 and 
Supplementary Table S1), tumor to organ ratios (Figure 3 and Supplementary Table S2) and 
contrast index (CI) (Figures 4 and Supplementary Table S3).    
 
Different fluorescent pHLIP
®
 peptides demonstrate different kinetic profiles (Figure 2 and 
Supplementary Table S1). The highest tumor targeting was observed at 2 or 4 hours post-
injection with subsequent decay of the signal. Most fluorescent pHLIP
®
 peptides have low liver 
accumulation except of Cy5.5-pHLIPs, which are the most hydrophobic construct among the 
investigated. We also performed study with Cy7.5-Var3, which is even more hydrophobic, and 
observed significant liver accumulation (data not shown). Surprisingly, Alexa546 pHLIP
®
 
peptides, which are second the most hydrophobic constructs after Cy5.5 pHLIP
®
 peptides, 
showed very low liver, kidney and muscle accumulation with the highest tumor targeting. Tumor 
to muscle ratio for Alexa546-Var3 was increasing from ~ 5 to 9 within 24 hrs (Figure 3 and 
Supplementary Table S2). With the shift to near infrared (NIR) wavelengths of excitation and 
emission for Alexa647, IR680 and Dy680 pHLIP
®
 peptides higher signal in kidney was 
monitored. Alexa750 and IR800 pHLIP
®
 peptides demonstrate the highest signal in the kidney 
and liver. We compared performance of Dy680 and its pegylated version, DyP680. The DyP680 
pHLIP
®
 peptides are more polar compared to Dy680 pHLIP
®
 peptides.  The most noticeable 
difference was observed in targeting of the kidney: DyP680 pHLIP
®
 peptides demonstrate about 
twice higher accumulation in the kidney than Dy680 pHLIP
®
 peptides, which could be related to 
the renal clearance. In overall the contrast index was enhanced for pegylated versions of the 
constructs compared to non-pegylated counterparts (Figure 4 and Supplementary Table S3). 
 
The contrast index was calculated only for two time points, 2 and 4 hours, since fluorescent 
signal in muscle at 24 and 48 hrs post-injection was at the level of the background fluorescence 
(Figure 4 and Supplementary Table S3). We did not observe any significant difference in CI 
between various pHLIP
®
 sequences, except of Alexa546-Var3, which showed statistically 
significant higher CI compared to Alexa546-WT and – Var7. The highest contrast (around 6) 
was observed for Alexa546-, Dy680- and DyP680 at 2 hrs post-injection. At 4 hrs the highest 
contrast of >8 was found for Cy5.5 pHLIP
®
 peptides. The lowest CI was detected for IR680 
pHLIP
®
 peptides.  
 We tested ability of pHLIP
®
 peptides to deliver imaging agents into the cell by conjugating 
Alexa546 and Cy5.5 dyes to the C-terminal part of Var3 of pHLIP
®
 peptide, which inserts into 
the lipid bilayer of membrane. We selected the most hydrophobic dyes to avoid complications 
with their translocation across cellular membrane. Our data indicate that CI was very similar for 
the constructs, where Alexa546 or Cy5.5 dyes were conjugated to the N- or C-terminus. We can 
conclude that Var3 pHLIP
®
 peptide is capable of delivering of imaging agents not only to the 
cell surface but also across membrane into a cell. However, the polarity of imaging agent will 
affect the process of its cellular delivery. Also, we evaluated performance of modified Var3M 
and Var7M, where several Asp residues were added to the N-terminus of the peptides. The 
statistically significant improvement was observed only for Alexa750-Var7M compared to 
Alexa750-Var7.   
 
To evaluate similarities and differences between investigated constructs we applied statistical 
agglomerative hierarchical clustering (tree-clustering) algorithm to the database of 24 objects 
comprising four normalized fluorescence parameters (NFT, NFM, NFL, NFK) obtained on 3 
different pHLIP
®
 variants conjugated with 8 fluorescent dyes and measured at time points of 2 
and 4 hours. The purpose of the algorithm is to build a tree-based hierarchical clustering 
solution, or dendrogram, to illustrate the similarities between the constructs and the order at 
which they merge into clusters. The dendrograms for 2 and 4 hours time points were constructed 
by joining of objects into clusters by using Euclidian measure of distance between objects in the 
multi-dimensional space of analyzed fluorescent parameters, and then applying an amalgamation 
Ward’s (linkage) rule [22] (Figure 5). The dendrogram height, which reflects the level of 
dissimilarity of clusters, was scaled to percentage for convenience of interpretation. The 
constructs merged at the lower levels of height are more similar in terms of fluorescent 
parameters than those merged at the higher levels. Significant changes in height in the 
dendrogram may indicate the data partition into appropriate number of clusters. We chose 
clustering algorithm because it does not require any a priori assumption about data distribution 
and allows us to reveal naturally existing classes and quantitatively estimate degrees of their 
distinctions, oppose to commonly used k-means or model-based clustering hierarchical 
approaches, which require a pre-defined number of classes. Our analysis allowed to reveal two 
main clusters, one is containing pHLIP
®
 peptides labeled with NIR dyes (Alexa750 and IR800) 
and Cy5.5 dye. The other cluster includes pHLIP
®
 peptides labeled with Alexa546, Alexa647, 
Dy680 and DyP680 fluorescent dyes. It was very clear separation of the cluster containing three 
pHLIP
®
 variants conjugated to Cy5.5 from the cluster of pHLIP
®
 peptides labeled with NIR 
dyes. 
 
We also performed multivariate linear regression analysis on a combined (not averaged) 
response of four fluorescent variables represented by NFT, NFM, NFL and NFK, and three 
categorical predictors represented by Time (2, 4 and 24 hours), Dye (8 various fluorescent dyes), 
and pHLIP
®
 sequences (Var3, Var7, and WT). Unlike linear regression performed on each 
fluorescence parameter separately, multivariate regression takes into account natural correlation 
between all four parameters. Model coefficients are summarized in Table 2. All coefficients 
marked by bold color indicate significant difference from corresponding reference levels. The 
obtained data indicate that the fluorescent signal in tumors and kidneys drops significantly only 
at 24 hours after constructs administration, while fluorescence in muscle and liver changes over 
all period of time (4 and 24 hrs). The most significant difference in tumor and organs targeting is 
observed for Cy5.5 pHLIP
®
 conjugates. Another group of constructs, which have altered 
accumulations in organs, consists of the NIR (IR680, IR800 and Al750) pHLIP
®
 peptides. These 
data are in very good agreement with the results of cluster analysis. Finally, fluorescent Var7 and 
WT pHLIP
®
 constructs demonstrate statistically significant reduction in tumor targeting 
compared to fluorescent Var3 pHLIP
®
 constructs. 
 
The Alexa546-Var3 construct was selected for testing of targeting of submillimeter metastatic 
lesions in lungs. Since 4T1 cells implanted into mice have stable expression of GFP the lesions 
were identified by GFP fluorescence on the excised fresh lungs tissue by fluorescence 
microscopy (Figure 6). The GFP signal has excellent co-localization with the Alexa546-Var3 
fluorescent indicating that 400-600 m sized metastatic lesions are acidic and targeted by 
fluorescent pHLIP
®
 peptide. 
 
DISCUSSION  
The approach for targeting of tumors, which we develop, is based on the marking of tumor 
acidity associated with tumor development, progression, aggressiveness and invasiveness.  We 
have shown previously, that peptides of pHLIP
®
 family deliver optical, PET and SPECT imaging 
agents to the primary tumors and metastatic lesions in a pH-dependent manner [9, 23-26]. Here 
we carried out a systematic investigation of targeting of 4T1 mammary tumors, kidney, liver and 
muscle at different time points after single intravenous administration of various pHLIP
®
 
peptides conjugated with eight different fluorescent dyes. Since the most NIR fluorescent dyes 
are large cyclic molecules (about 1 kDa in mass) they can affect and alter biodistribution of 
pHLIP
®
 peptides (about 4 kDa in mass). All fluorescent pHLIP
®
 peptides show slow tumor 
targeting, which ranged within hours after constructs administration. It is advantageous for drug 
delivery, since it could enhance pHLIP
®
 peptide-drug circulation in blood. The best tumor 
targeting was observed for pHLIP
®
 variants (WT, Var3 and Var7) conjugated with Alexa546 at 
both N- or C-termini of the peptides to tether dye to the membrane of cancer cells in the 
extracellular or intracellular spaces, respectively. Accumulation of the Alexa546 pHLIP
®
 
peptides in other organs and tissue was about 4 times less than in tumor. Thus, Alexa546 
potentially can alter biodistribution of pHLIP
®
 peptides in a favorable way, and might be used 
with pHLIP
®
 peptide-drug conjugates. According to our data, Var3 demonstrates the highest 
tumor targeting in the most cases. We also showed targeting of submillimeter metastatic lesions 
in lungs by Alexa546-Var3, which opens opportunity of imaging and treating of metastasis 
employing pHLIP
®
 technology.   
 
The fluorescent pHLIP
®
 peptides also could have important implication for staining and 
visualization of cancer cells during surgical procedures [27].  Fluorescence-guided surgery has 
the promise to improve surgical procedures by determining tumor margins using tumor-specific 
targeting and by increasing the visual information available to the surgeon [28]. This technique, 
can possibly lead to complete resection of the tumor tissue with improved survival. On the 
foundation of the hallmarks of cancer, there is a variety of tumor-specific agents that are 
available for imaging of cancer [29]. To obtain target-specific fluorescence imaging, the contrast 
agent has to be sent to the tumor site, and has to be kept by the target while non-bound agents are 
cleared from the circulation. Mostly, NIR dyes are suited better for tissue staining, since auto 
fluorescence signal in NIR is much lower compared to visible light. The biodistribution is less 
critical, however the highest possible contrast between cancerous and normal tissue is the key. 
Var3 conjugated either with N- or C-terminus with Alexa546 or Cy5.5 show the highest tumor 
accumulation and highest contrast between tumor and normal tissue. Among NIR dyes, 
Alexa750, IR800 or Dy680 and DyP680 might be used for surgical procedures. 
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FIGURES LEGENDS 
Figure 1. Distribution of the fluorescent pHLIP
®
 peptides in 4T1 mammary tumors (cut in 
half), muscle, kidney and liver. Fluorescent images of tissue and organs were obtained at 4 hrs 
post-injection (p.i.) after single i.v. administration of WT, Var3 and Var7 peptides conjugated 
with fluorescent dyes. 
Figure 2. Time-dependent distribution of the fluorescent pHLIP
®
 peptides in 4T1 
mammary tumors, kidney, liver and muscle quantified by the ex-vivo mean fluorescence. 
The data in each row were normalized to the intensity in tumor of the corresponding fluorescent 
WT pHLIP
®
 peptide at 2 hours p.i.. The numeric values of non-normalized fluorescent intensities 
are presented in the Supplementary Table 1. 
Figure 3. Tumor to organ ratios calculated for 2, 4 and 24 hrs time points p.i.. The numeric 
values of tumor to organ ratios are presented in the Supplementary Table 2.  
Figure 4. Contrast index (CI) calculated at 2 and 4 hrs time points p.i.. The p-level values 
were computed based on the two-tailed test, * < 0.05 and ** < 0.005. The red asterisk represent 
p-level calculated for CI between Dy680-WT and DyP680-WT, Dy680-Var7 and DyP680-Var7. 
The numeric values of CI are presented in the Supplementary Table 3. 
Figure 5. Multivariate statistical analysis. The dendrograms obtained for imaging properties of 
various fluorescent pHLIP
®
 peptides at 2 and 4 hrs time points p.i. 
Figure 6. Targeting of submillimeter metastatic lesions in lungs. 4T1-GFP cells were injected 
subcutaneously in the mammary pad of the mouse. After 3 weeks, the primary tumor 
metastasized in the lungs. The Alexa546-Var3 was given as a single  i.v. tail vein injection. At 4 
hrs p.i. animals were euthanized, the lungs were excised and imaged immediately on the 
fluorescent microscope. 
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TABLES 
Table 1.  Spectral properties (position of maximum of excitation, ex, and emission, em), 
molecular weights and HPLC retention times of the fluorescent pHLIP
®
 constructs are shown. 
Spectral Properties  
 Al546 Al647 Al750 Cy5.5 IR680 IR800 Dy680 DyP680 
ex, nm 
em, nm 
556 
572 
650 
670 
753 
778 
630/673 
720 
672 
702 
778 
797 
680 
707 
680 
707 
Molecular Weights 
WT 5146 5362 5462 4853 5140 5303 5084 5866 
Var3 4256 4472 4572 3963 4250 4413 4194 4976 
Var7 4100 4316 4416 3807 4094 4257 4038 4820 
Var3-C 4313 - - 4020 - - - - 
HPLC Retention Times 
WT 29.2 24.8 25.3 29.4 25.5 25.0 26.2 24.9 
Var3 27.6 23.3 23.6 28.4 24.3 23.4 25.0 23.7 
Var7 25.7 21.6 22.0 26.9 22.8 21.6 23.9 22.0 
Var3-C 27.5 - - 29.8 - - - - 
 
  
Table 2. The coefficients obtained using multivariate linear regression on a combined response 
of four fluorescence variables represented by NFT (normalized fluorescence in tumor), NFM 
(normalized fluorescence in muscle), NFL (normalized fluorescence in liver) and NFK 
(normalized fluorescence in kidney), and three categorical predictors represented by Time (2, 4 
and 24 hours), Dye (8 various fluorescent dyes), and pHLIP
®
 variants (Var3, Var7, and WT). All 
coefficients marked by bold color indicate significant difference from corresponding reference 
level. The intercept values correspond to the averages of four fluorescence variables at the 
reference levels of the predictors: Time = 2 hours, Dye = Al546, and pHLIP
® 
variant = Var3. 
 
 
  
  NFT NFM NFL NFK 
Intercept 1.325 0.312 0.685 0.615 
Time 
2h  (Reference) 
4h  
24h 
0 
0.058 
-0.548 
0 
-0.033 
-0.190 
0 
-0.178 
-0.678 
0 
-0.101 
-0.615 
 
Dye 
Al546 (Reference) 
Al647 
Dy680 
DyP680 
IR680 
Al750 
IR800 
Cy5.5 
0 
 0.002 
-0.321 
-0.300 
-0.019 
-0.178 
0.091 
0.215 
0 
0.093 
-0.017 
-0.047 
0.321 
0.007 
0.087 
0.081 
0 
0.293 
0.084 
0.041 
0.427 
0.549 
1.147 
1.701 
0 
1.036 
0.171 
1.132 
0.483 
1.860 
2.274 
0.635 
 
pHLIP
®
 variant 
Var3 (Reference) 
Var7 
0 
-0.530 
-0.226 
0 
-0.094 
-0.029 
0 
-0.380 
-0.074 
0 
-0.181 
-0.178 WT 
Adjusted R-squared 0.6986 0.8127 0.780 0.814 
FIGURES 
 
 
Figure 1 
 Figure 2 
 Figure 3  
 Figure 4 
  
 Figure 5  
  
Figure 6  
  
SUPPLEMENTARY MATERIAL 
Comparative study of tumor targeting and biodistribution of pH (Low) Insertion Peptides 
(pHLIP
®
 peptides) conjugated with different fluorescent dyes 
 
Ramona-Cosmina Adochite, Anna Moshnikova, Jovana Golijanin, Oleg A. Andreev, Natallia 
Katenka, Yana K. Reshetnyak 
 
Table S1. Mean surface fluorescence obtained from the organs and tissue at different time points 
after single i.v. administration of the fluorescent constructs.  Values for the control represent 
baseline autofluorescence signal from animals with no injection of fluorescent constructs. The 
number of animals for each time point and each construct is indicated by n. 
 
Alexa546-pHLIPs 
Organs 
Time 
post-
injection 
WT 
n=6 
Var3 
n=6 
Var3-C 
n=3 
Var7 
n=6 
Control 
Muscle 
2 hrs 
4 hrs 
24 hrs 
48 hrs 
1057.0 ±137.8 
1212.0 ± 189.4 
249.4 ± 23.2 
193.6 ± 18.0 
963.4 ± 120.8 
1117.9 ± 167.3 
297.7 ± 28.6 
201.0 ± 13.3 
281.6 ± 23.3 
283.8 ± 52.6 
209.5 ± 18.6 
1150.2 ± 126.6 
756.9 ± 34.9 
191.2 ± 8.34 
179.4 ±16.1 
156.3 
Tumor 
2 hrs 
4 hrs 
24 hrs 
48 hrs 
3856.7 ± 1058.5 
5716.8 ± 1284.8 
1287 ± 290.4 
999.5 ± 129.8 
4664.5 ± 720.4 
5809.9 ± 880.4 
2772.9 ± 600.3 
1229.6 ± 281.9 
834.6 ± 86.6 
847.3 ± 162.2 
1168.5 ± 299.8 
3267.1 ± 690.0 
3514.1 ± 622.9 
810.4 ± 196.2 
516.7 ± 128.9 
170.2 
Liver 
2 hrs 
4 hrs 
24 hrs 
48 hrs 
1671.7 ± 148.7 
1984.0  ± 27.9 
502.5 ± 85.6 
357.2 ± 24.6 
1670.3 ± 409.5 
1448.7 ± 317.7 
303.4 ± 64.4 
254.9 ± 37.2 
380.3 ± 39.2 
288.4 ± 11.8 
229.5 ± 17.6 
805.8 ± 112.4 
623.6 ± 77.2 
217.0 ± 21.8 
193 ± 20.6 
144.2 
Kidney 
2 hrs 
4 hrs 
24 hrs 
48 hrs 
1235.5 ± 182.2 
1099.2 ± 254.3 
544.8 ± 85.9 
485.4 ± 126.5 
880.3 ± 51.2 
1148.4 ± 326.7 
1288.7 ± 253.3 
918.5 ± 225.9 
326.8 ± 83.1 
327.7 ± 41.3 
291.9 ± 17.9 
1346.8 ± 145.8 
1045.2 ± 144.4 
821.3 ± 122.5 
690.5 ± 259.6 
156.4 
Alexa647-pHLIPs 
Organs 
Time 
post-
injection 
WT 
n=3 
Var3 
n=3 
Var7 
n=3 
Control 
Muscle 
2 hrs 
4 hrs 
24 hrs 
2617.5 ± 616.0 
2093.2 ± 111.4 
932.8 ± 49.0 
4940.6 ± 527.6 
3467.6 ± 839.4 
1054.8 ± 121.0 
1818.8 ± 200.0 
1569.0 ± 275.9 
1016.0 ± 171.7 
980.7 
Tumor 
2 hrs 
4 hrs 
7498.5 ± 1480.5 
6798.8 ± 221.9 
14565.3 ± 1577.3 
12099.6 ±255.7 
6556.0 ± 1013.2 
4781.5 ± 675.1 
1125.5 
24 hrs 2480.1 ± 290.3 3948.6 ± 2212.7 2832.5 ± 588.2 
Liver 
2 hrs 
4 hrs 
24 hrs 
5311.2 ± 97.9 
5137.2 ± 1330.5 
1680.4 ± 490.3 
9832.4 ± 622.3 
7615.7 ± 1028.3 
1327.4 ± 298.0 
2598.1 ± 335.6 
1921.6 ± 351.0 
1091.4 ± 175.4 
525.6 
Kidney 
2 hrs 
4 hrs 
24 hrs 
8516.0 ± 1611.7 
9135.8 ± 1167.8 
3778.7 ± 550.7 
16126.9 ± 2787.4 
14325.3 ± 1332.3 
6081.2 ± 2036.8 
10112.8 ± 391.6 
10696.1 ± 1726.5 
8461.9 ± 4773.8 
552.6 
Alexa750-pHLIPs 
Organs 
Time 
post-
injection 
WT 
n=3 
Var3 
n=3 
Var7 
n=3 
Control 
Muscle 
2 hrs 
4 hrs 
24 hrs 
48 hrs 
889.8 ± 87.2 
700.2 ± 117.8 
275.5 ± 10.1 
168.7 ± 7.3 
1002.6 ± 30.7 
836.3 ± 123.7 
228.0 ± 24.5 
150.4 ± 4.2 
749.4 ± 21.4 
401.0 ± 40.8 
169.0 ± 10.8 
144.8 ± 0.3 
127.3 
Tumor 
2 hrs 
4 hrs 
24 hrs 
48 hrs 
2847.7 ± 40.1 
2897.5 ± 610.4 
1118.9 ± 76.5 
414.6 ± 23.7 
3800.4 ± 226.1 
3542.2 ± 431.8 
650.9 ± 88.8 
236.8 ± 15.7 
2301.2 ± 172.6 
1256.4 ± 110.8 
260.7 ± 10.3 
180.8 ± 16.9 
135.4 
Liver 
2 hrs 
4 hrs 
24 hrs 
48 hrs 
3577.2 ± 375.5 
3776.3 ± 1111.3 
1370.9 ± 104.7 
363.1 ± 36.6 
4618.6 ± 183.6 
2401.4 ± 344.5 
553.2 ± 46.8 
286.9 ± 11.6 
1722.5 ± 350.7 
1087.8 ± 13.4 
342.7 ± 19.3 
226.8 ± 21.7 
140.3 
Kidney 
2 hrs 
4 hrs 
24 hrs 
48 hrs 
7413.1 ± 881.7 
7664.2 ± 1328.6 
2459.8 ± 164.2 
491.2 ± 50.3 
9417.1 ± 862.6 
7891.6 ± 984.4 
1869.1 ± 197.4 
487.5 ± 74.6 
7146.2 ± 419.3 
7131.0 ± 552.1 
1836.9 ± 236.7 
429.2 ± 16.6 
143.5 
Alexa750-pHLIP-Mutants 
Organs 
Time 
post-
injection 
Var3M 
n=3 
Var7M 
n=3 
Control 
Muscle 
2 hrs 
4 hrs 
886.2 ± 197.3 
774.2 ± 255.2 
628.3 ± 24.2 
430.1 ± 47.1 
146.9 
Tumor 
2 hrs 
4 hrs 
3444.6 ± 311.3 
3355.9 ± 796.2 
2451.8 ± 162.1 
1562.9 ± 240.4 
144.1 
Liver 
2 hrs 
4 hrs 
3954.1 ± 46.2 
2313.2 ± 373.7 
1389.4 ± 129.5 
902.0 ± 79.4 
144.2 
Kidney 
2 hrs 
4 hrs 
9114.2 ± 529.2 
8615.9 ± 657.4 
9691.2 ± 176.0 
8275.0 ± 499.0 
146.5 
 
Cy5.5-pHLIPs 
Organs 
Time 
post-
injection 
WT 
n=3 
Var3 
n=3 
Var3-C 
n=3 
Var7 
n=3 
Control 
Muscle 
2 hrs 
4hrs 
24hrs 
634.1 ± 83.7 
652.3 ± 88.4 
466.5 ± 54.2 
918.8 ± 162.6 
660.5 ± 36.6 
424.2 ± 30.8 
1035.1 ± 63.4 
719.4 ± 113.4 
411.3 ± 4.4 
638.0 ± 86.3 
467.3 ± 63.0 
356.7 ± 16.5 
276.1 
Tumor 
2 hrs 
4hrs 
24hrs 
2094.8 ± 497.0 
2882.6 ± 660.6 
2419.5 ± 226.1 
3343.2 ± 1526.1 
2798.5 ± 395.2 
2312.5 ± 556.1 
3627.7 ± 441.5 
3482.0 ± 502.7 
2371.9 ± 186.9 
1900.3 ± 293.5 
2076.3 ± 531.5 
1390.8 ± 141.9 
316.9 
Liver 
2 hrs 
4hrs 
24hrs 
4209.2 ± 603.7 
3587.1 ± 127.3 
2666.9 ± 229.0 
8118.0 ± 901.8 
5589.0 ± 129.6 
1513.1 ± 248.1 
7828.1 ± 1161.2 
5916.4 ± 843.6 
1844.5 ± 437.3 
5706.9 ± 719.4 
4177.2 ± 278.0 
1180.8 ± 197.8 
259.5 
Kidney 
2 hrs 
4hrs 
24hrs 
2024.9 ± 349.3 
1576.9 ± 253.7 
947.9 ± 198.0 
2641.0 ± 249.2 
1998.0 ± 485.3 
1135.4 ± 193.9 
2926.5 ± 223.8 
2322.7 ± 335.8 
1116.7 ± 28.6 
2729.3 ± 137.4 
2416.3 ± 588.9 
1335.8 ± 174.5 
263.9 
IR680-pHLIPs 
Organs 
Time post-
injection 
WT 
n=3 
Var3 
n=3 
Var7 
n=3 
Control 
Muscle 
2 hrs 
4 hrs 
24 hrs 
523.3 ± 32.9 
551.6 ± 80.0 
353.6 ± 37.5 
619.2 ± 50.7 
659.5 ± 56.9 
401.9 ± 53.1 
463.5 ± 73.9 
401.0 ± 44.6 
363.4 ± 23.2 
324.1 
Tumor 
2 hrs 
4 hrs 
24 hrs 
931.9 ± 18.8 
906.3 ± 66.0 
426.7 ± 5.5 
1370.8 ± 158.3 
1462.7 ± 114.7 
645.5 ± 185.8 
718.9 ± 83.5 
597.8 ± 69.8 
719.7 ± 34.1 
333.1 
Liver 
2 hrs 
4 hrs 
24 hrs 
917.9 ± 144.1 
626.3 ± 52.6 
305.8 ± 35.3 
1119.3 ± 97.7 
1020.2 ± 150.4 
389.4 ± 53.3 
569.2 ± 33.3 
427.7 ± 47.2 
291.5 ± 33.0 
270.3 
Kidney 
2 hrs 
4 hrs 
24 hrs 
1053.0 ± 171.0 
758.6 ± 137.3 
353.6 ± 37.5 
821.8 ± 30.6 
830.5 ± 52.5 
352.4 ± 89.0 
1081.4 ± 76.1 
682.6 ± 107.8 
311.6 ± 34.1 
241.7 
IR800-pHLIPs 
Organs 
Time post-
injection 
WT 
n=3 
Var3 
n=3 
Var7 
n=3 
Control 
Muscle 
2 hrs 
4 hrs 
24 hrs 
630.6 ± 53.2 
612.6 ± 25.1 
255.6 ± 19.7 
736.4 ± 116.0 
747.9 ± 10.5 
231.6 ± 21.1 
542.9 ± 43.0 
359.1 ± 27.7 
185.1 ± 14.6 
127.3 
Tumor 
2 hrs 
4 hrs 
24 hrs 
1684.9 ± 292.6 
1996.4 ± 581.3 
737.5 ± 241.1 
2289.3 ± 146.0 
3129.0 ± 176.4 
1349.9 ± 267.3 
1858.2 ± 271.3 
1585.9 ± 165.8 
554.9 ± 156.6 
135.4 
Liver 2 hrs 3133.4 ± 179.7 3849.9 ± 164.7 2337.0 ± 107.9 140.3 
4 hrs 
24 hrs 
2969.8 ± 512.7 
1863.4 ± 201.1 
3238.8 ± 127.2 
1089.6 ± 165.0 
1964.7 ± 129.2 
972.4 ± 149.9 
Kidney 
2 hrs 
4 hrs 
24 hrs 
4529.1 ± 547.1 
4015.6 ± 861.0 
2998.4 ± 314.5 
5908.6 ± 128.3 
6235.9 ± 470.1 
3863.7 ± 478.2 
3885.1 ± 420.8 
3238.1 ± 345.6 
3696.5 ± 114.7 
143.5 
Dy680-pHLIPs 
Organs 
Time post-
injection 
WT 
n=3 
Var3 
n=3 
Var7 
n=3 
Control 
Muscle 
2 hrs 
4 hrs 
24 hrs 
754.9 ± 106.3 
694.3 ± 50.6 
203.6 ± 4.8 
465.4 ± 103.5 
533.2 ± 18.3 
274.6 ± 15.8 
345.6 ± 4.7 
305.5 ± 16.4 
178.9 ± 9.2 
172.3 
Tumor 
2 hrs 
4 hrs 
24 hrs 
2326.0 ± 183.6 
2246.3 ± 627.8 
511.7 ± 129.3 
1998.2 ± 394.4 
2243.3 ± 103.9 
897.0 ± 314.3 
1029.3 ± 100.8 
847.4 ± 73.5 
241.1 ± 7.8 
219.0 
Liver 
2 hrs 
4 hrs 
24 hrs 
1600.0 ± 60.7 
1284.6 ± 142.6 
331.8 ± 46.2 
1243.7 ± 218.2 
984.2 ± 47.5 
373.0 ± 49.8 
495.5 ± 77.8 
431.2 ± 65.6 
207.5 ± 20.6 
210.9 
Kidney 
2 hrs 
4 hrs 
24 hrs 
1886.5 ± 227.5 
1728.6 ± 45.4 
327.9 ± 29.1 
1066.6 ± 119.8 
1088.9 ± 73.8 
375.4 ± 39.5 
1242.9 ± 119.1 
1004.5 ± 250.7 
229.8 ± 22.6 
160.2 
DyP680-pHLIPs 
Organs 
Time post-
injection 
WT 
n=3 
Var3 
n=3 
Var7 
n=3 
Control 
Muscle 
2 hrs 
4 hrs 
24 hrs 
829.6 ± 165.3 
735.1 ± 137.6 
478.9 ± 24.9 
828.6 ± 389.7 
808.5 ± 14.8 
406.4 ± 27.0 
416.5 ± 22.7 
367.0 ± 58.5 
291.1 ± 22.2 
172.3 
Tumor 
2 hrs 
4 hrs 
24 hrs 
3832.7 ± 769 
3679.4 ± 225.9 
2716.2 ± 512.0 
2883.7 ± 567.7 
3104.6 ± 162.4 
2239.8 ± 459.6 
936.2 ± 132.2 
1008.8 ± 166.8 
644.9 ± 60.6 
219.0 
Liver 
2 hrs 
4 hrs 
24 hrs 
1968.9 ± 354.6 
1726.6 ± 343.2 
1290.2 ± 82.3 
1614.4 ± 152 
1517.9 ± 26.1 
650.6 ± 131.0 
488.2 ± 38.9 
405.6 ± 71.1 
314.1 ± 27.1 
210.9 
Kidney 
2 hrs 
4 hrs 
24 hrs 
6047.7 ± 619.5 
4757.6 ± 360.8 
5010.1 ± 364.3 
6584.5 ± 640.1 
4896.5 ± 656.5 
5269.3 ± 923.6 
5262.3 ± 562.0 
5459.7 ± 928.5 
4576.4 ± 489.9 
160.2 
 
 
 
 
 
Table S2. Tumor/muscle, tumor/kidney and tumor/liver ratio values. 
Ratios Time post-
injection 
WT 
 
Var3 
 
Var7 
 
Alexa546-pHLIPs 
Tumor/Muscle 
2 hrs 
4 hrs 
24 hrs 
3.62 ± 0.77 
4.68 ± 0.57 
5.22 ± 1.47 
4.86 ± 0.75 
5.29 ± 1.27 
9.32 ± 1.45 
2.89 ± 0.76 
4.62 ± 0.67 
4.23 ± 1.00 
Tumor/Kidney 
2 hrs 
4 hrs 
24 hrs 
3.13 ± 0.84 
5.39 ± 1.70 
2.45 ± 0.80 
5.30 ± 0.83 
5.23 ± 1.18 
2.21 ± 0.52 
2.40 ± 0.26 
3.36 ± 0.36 
1.03 ± 0.38 
Tumor/Liver 
2 hrs 
4 hrs 
24 hrs 
2.31 ± 0.60 
2.88 ± 0.62 
2.67 ± 1.03 
2.83 ± 0.36 
4.09 ± 0.98 
9.57 ± 3.14 
4.09 ± 0.80 
5.60 ± 0.36 
3.76 ± 1.02 
Alexa647-pHLIPs 
Tumor/Muscle 
2 hrs 
4 hrs 
24 hrs 
2.88 ± 0.21 
3.25 ± 0.12 
2.67 ± 0.44 
2.95 ± 0.26 
3.61 ± 0.81 
3.62 ± 1.66 
3.60 ± 0.23 
3.09 ± 0.58 
2.81 ± 0.63 
Tumor/Kidney 
2 hrs 
4 hrs 
24 hrs 
0.68 ± 0.55 
0.75 ± 0.12 
0.66 ± 0.04 
0.93 ± 0.26 
0.85 ± 0.09 
0.62 ± 0.16 
0.65 ± 0.10 
0.45 ± 0.05 
0.38 ± 0.14 
Tumor/Liver 
2 hrs 
4 hrs 
24 hrs 
1.42 ± 0.30 
1.34 ± 0.41 
1.53 ± 0.28 
1.48 ± 0.09 
1.61 ± 0.27 
2.82 ± 1.04 
2.52 ± 0.07 
2.51 ± 0.25 
2.64 ± 0.70 
Alexa750-pHLIPs 
Tumor/Muscle 
2 hrs 
4 hrs 
24 hrs 
3.22 ± 0.18 
4.16 ± 0.29 
4.06 ± 0.10 
3.80 ± 0.18 
4.33 ± 0.59 
2.88 ± 0.30 
3.08 ± 0.18 
3.14 ± 0.11 
1.54 ± 0.03 
Tumor/Kidney 
2 hrs 
4 hrs 
24 hrs 
0.39 ± 0.03 
0.39 ± 0.04 
0.46 ± 0.03 
0.41 ± 0.03 
0.45 ± 0.02 
0.35 ± 0.04 
0.32 ± 0.02 
0.18 ± 0.01 
0.14 ± 0.01 
Tumor/Liver 
2 hrs 
4 hrs 
24 hrs 
0.80 ± 0.05 
0.80 ± 0.08 
0.82 ± 0.07 
0.82 ± 0.03 
1.48 ± 0.05 
1.17 ± 0.04 
1.36 ± 0.12 
1.15 ± 0.05 
0.76 ± 0.04 
Cy5.5-pHLIPs 
Tumor/Muscle 
2 hrs 
4 hrs 
24 hrs 
3.28 ± 0.23 
4.50 ± 0.71 
5.27 ± 0.63 
3.54 ± 0.57 
4.23 ± 0.25 
5.41 ± 0.53  
3.02 ± 0.37 
4.39 ± 0.32 
3.91 ± 0.30 
Tumor/Kidney 
2 hrs 
4 hrs 
24 hrs 
1.04 ± 0.09 
 1.83 ± 0.19 
2.60 ± 0.20 
1.26 ± 0.31 
1.42 ± 0.08 
2.11 ± 0.47 
0.70 ± 0.07 
0.88 ± 0.15 
1.06 ± 0.13 
Tumor/Liver 
2 hrs 
4 hrs 
24 hrs 
0.50 ± 0.04 
0.80 ± 0.11 
0.91 ± 0.07 
0.41 ± 0.09 
0.50 ± 0.03 
1.52 ± 0.10 
0.34 ± 0.05 
0.49 ± 0.06 
1.20 ± 0.14 
IR680-pHLIPs 
Tumor/Muscle 
2 hrs 
4 hrs 
24 hrs 
1.79 ± 0.14 
1.67 ± 0.26 
1.22 ± 0.12 
2.21 ± 0.08 
2.22 ± 0.12 
1.58 ± 0.28 
1.57 ± 0.23 
1.50 ± 0.21 
1.16 ± 0.13 
Tumor/Kidney 
2 hrs 
4 hrs 
24 hrs 
0.90 ± 0.16 
1.21 ± 0.17 
1.37 ± 0.12 
1.67 ± 0.24 
1.76 ± 0.12 
1.82 ± 0.23 
0.66 ± 0.06 
0.89 ± 0.12 
1.36 ± 0.25 
Tumor/Liver 
2 hrs 
4 hrs 
24 hrs 
1.03 ± 0.19 
1.46 ± 0.18 
1.40 ± 0.16 
1.23 ± 0.11 
1.45 ± 0.34 
1.64 ± 0.32 
1.26 ± 0.10 
1.40 ± 0.20 
1.45 ± 0.12 
IR800-pHLIPs 
Tumor/Muscle 
2 hrs 
4 hrs 
24 hrs 
2.70 ± 0.66 
3.24 ± 0.82 
2.88 ± 0.92 
3.15 ± 0.37 
4.18 ± 0.18 
5.79 ± 0.67 
3.46 ± 0.72 
4.45 ± 0.80 
2.97 ± 0.61 
Tumor/Kidney 
2 hrs 
4 hrs 
24 hrs 
0.38 ± 0.09 
0.50 ± 0.10 
0.24 ± 0.06 
0.39 ± 0.02 
0.50 ± 0.02 
0.35 ± 0.05 
0.48 ± 0.02 
0.49 ± 0.02 
0.15 ± 0.04 
Tumor/Liver 
2 hrs 
4 hrs 
24 hrs 
0.54 ± 0.07 
0.67 ± 0.15 
0.39 ± 0.12 
0.59 ± 0.04 
0.97 ± 0.08 
1.23 ± 0.12 
0.80 ± 0.11 
0.80 ± 0.08 
0.56 ± 0.07 
Dy680-pHLIPs 
Tumor/Muscle 
2 hrs 
4 hrs 
24 hrs 
3.11 ± 0.29 
3.28 ± 1.09 
2.51 ± 0.61 
4.32 ± 0.53 
4.21 ± 0.33 
3.25 ± 1.02 
2.98 ± 0.33 
2.77 ± 0.10 
1.35 ± 0.03 
Tumor/Kidney 
2 hrs 
4 hrs 
24 hrs 
1.24 ± 0.29 
1.30 ± 0.39 
1.58 ± 0.48 
1.86 ± 0.20 
2.06 ± 0.06 
2.40 ± 0.90 
0.83 ± 0.02 
0.87 ± 0.18 
1.05 ± 0.07 
Tumor/Liver 
2 hrs 
4 hrs 
24 hrs 
1.45 ± 0.09 
1.77 ± 0.56 
1.53 ± 0.19 
1.60 ± 0.10 
2.29 ± 0.21 
2.38 ± 0.64 
2.09 ± 0.15 
1.99 ± 0.25 
1.17 ± 0.08 
DyP680-pHLIPs 
Tumor/Muscle 
2 hrs 
4 hrs 
24 hrs 
4.62 ± 0.19 
5.15 ± 1.14 
5.65 ± 0.81 
3.86 ± 1.22 
3.84 ± 0.13 
5.48 ± 0.84 
2.24 ± 0.23 
2.78 ± 0.59 
2.21 ± 0.04 
Tumor/Kidney 
2 hrs 
4 hrs 
24 hrs 
0.64 ± 0.15 
0.78 ± 0.09 
0.55 ± 0.12 
0.44 ± 0.09 
0.64 ± 0.11 
0.42 ± 0.03 
0.18 ± 0.02 
0.19 ± 0.01 
0.14 ± 0.02 
Tumor/Liver 
2 hrs 
4 hrs 
24 hrs 
1.94 ± 0.14  
2.17 ± 0.31 
2.11 ± 0.40 
1.78 ± 0.23 
2.05 ± 0.12 
3.44 ± 0.02 
1.92 ± 0.27 
2.49 ± 0.03 
2.06 ± 0.19 
 
  
Table S3. Contrast Index (CI) calculated for 2 and 4 hours time points. 
Time post-
injection 
WT 
 
Var3 
 
Var7 
 
Alexa546-pHLIPs 
2 hrs 
4 hrs 
4.06 ± 0.88 
5.22 ± 0.61 
5.60 ± 0.92 
6.01 ± 1.55 
3.18 ± 0.90 
5.54 ± 0.81 
Alexa647-pHLIPs 
2 hrs 
4 hrs 
4.03 ± 0.58 
5.12 ± 0.39 
3.41 ± 0.35 
4.72 ± 1.39 
2.61 ± 0.07 
7.18 ± 3.70 
Alexa750-pHLIPs 
2 hrs 
4 hrs 
3.59 ± 0.40 
4.88 ± 0.92 
4.19 ± 0.37 
4.95 ± 1.28 
3.49 ± 0.39 
4.13 ± 0.39 
Cy5.5-pHLIPs 
2 hrs 
4 hrs 
4.96 ± 0.56 
7.16 ± 2.54 
4.55 ± 1.19 
6.44 ± 0.63 
4.58 ± 1.47 
9.27 ± 0.37 
IR680-pHLIPs 
2 hrs 
4 hrs 
1.79 ± 0.14 
1.67 ± 0.26 
2.21 ± 0.08 
2.22 ± 0.12 
1.57 ± 0.23 
1.50 ± 0.21 
IR800-pHLIPs 
2 hrs 
4 hrs 
3.13 ± 0.87 
3.80 ± 0.10 
3.61 ± 0.55 
4.82 ± 0.21 
4.21 ± 1.00 
6.37 ± 1.46 
Dy680-pHLIPs 
2 hrs 
4 hrs 
3.67 ± 0.48 
3.97 ± 1.50 
6.27 ± 1.13 
5.63 ± 0.56 
4.69 ± 0.71 
4.72 ± 0.07 
DyP680-pHLIPs 
2 hrs 
4 hrs 
5.55 ± 0.40 
6.43 ± 1.50 
4.99 ± 2.44 
4.53 ± 0.15 
2.92 ± 0.36 
4.25 ± 1.40 
 
  
  
Figure S1. Absorption and fluorescence spectra of fluorescent-constructs measured in PBS. 
 
 
